淋巴水肿评估中的生物标志物:弹性成像和多频生物阻抗分析的整合。

IF 1.9 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Biomarkers in medicine Pub Date : 2024-10-24 DOI:10.1080/17520363.2024.2415283
Hyeonwoo Jeon, Doo Young Kim, Si-Woon Park, Bum-Suk Lee, Daham Kim, Hyeong-Wook Han, Namo Jeon
{"title":"淋巴水肿评估中的生物标志物:弹性成像和多频生物阻抗分析的整合。","authors":"Hyeonwoo Jeon, Doo Young Kim, Si-Woon Park, Bum-Suk Lee, Daham Kim, Hyeong-Wook Han, Namo Jeon","doi":"10.1080/17520363.2024.2415283","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Multi-frequency bioimpedance analysis (MFBIA) is used to measure lymphedema, but it is a biomarker that is sensitive to stiffness. Lymphedema is a condition that can be accompanied by stiffness, but no studies have considered this, so we tried to use non-invasive elastography as a biomarker for stiffness.<b>Methods & results:</b> This retrospective study included 102 patients with lymphedema, divided into two groups according to the elastography strain ratio: stiff group (elastography strain ratio <0.7, n = 48) and non-stiff group (elastography strain ratio >0.7, n = 54). We estimated the volume of the affected arm based the extracellular water (ECW) volume calculated using MFBIA through a simple linear regression method. The adjusted R2 was 0.044 in the stiff group and 0.729 in the non-stiff group. Stepwise multivariate linear regression was used to investigate the significant factors for estimating the affected arm volume for each group. In the non-stiff group, the significantly associated factors were impedance at 50 kHz, weight, and height (adjusted R<sup>2</sup> = 0.724; <i>p</i> = 0.003). In the stiff group, significant associations were observed among impedance at 250 kHz, impedance at 1 kHz, weight, and height (adjusted R<sup>2</sup> = 0.705, <i>p</i> = 0.041).<b>Conclusion:</b> Considering the characteristics of lymphedema, using MFBIA concurrently with elastography can be useful biomarker for estimating lymphedema.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-11"},"PeriodicalIF":1.9000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biomarkers in lymphedema assessment: integrating elastography and muti-frequency bioimpedance analysis.\",\"authors\":\"Hyeonwoo Jeon, Doo Young Kim, Si-Woon Park, Bum-Suk Lee, Daham Kim, Hyeong-Wook Han, Namo Jeon\",\"doi\":\"10.1080/17520363.2024.2415283\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> Multi-frequency bioimpedance analysis (MFBIA) is used to measure lymphedema, but it is a biomarker that is sensitive to stiffness. Lymphedema is a condition that can be accompanied by stiffness, but no studies have considered this, so we tried to use non-invasive elastography as a biomarker for stiffness.<b>Methods & results:</b> This retrospective study included 102 patients with lymphedema, divided into two groups according to the elastography strain ratio: stiff group (elastography strain ratio <0.7, n = 48) and non-stiff group (elastography strain ratio >0.7, n = 54). We estimated the volume of the affected arm based the extracellular water (ECW) volume calculated using MFBIA through a simple linear regression method. The adjusted R2 was 0.044 in the stiff group and 0.729 in the non-stiff group. Stepwise multivariate linear regression was used to investigate the significant factors for estimating the affected arm volume for each group. In the non-stiff group, the significantly associated factors were impedance at 50 kHz, weight, and height (adjusted R<sup>2</sup> = 0.724; <i>p</i> = 0.003). In the stiff group, significant associations were observed among impedance at 250 kHz, impedance at 1 kHz, weight, and height (adjusted R<sup>2</sup> = 0.705, <i>p</i> = 0.041).<b>Conclusion:</b> Considering the characteristics of lymphedema, using MFBIA concurrently with elastography can be useful biomarker for estimating lymphedema.</p>\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"1-11\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2024.2415283\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2024.2415283","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:多频生物阻抗分析(MFBIA)用于测量淋巴水肿,但它是一种对僵硬度敏感的生物标志物。淋巴水肿是一种可能伴有僵硬的疾病,但没有研究考虑到这一点,因此我们尝试使用无创弹性成像技术作为僵硬度的生物标志物:这项回顾性研究包括102名淋巴水肿患者,根据弹性成像应变比分为两组:僵硬组(弹性成像应变比为0.7,n = 54)。我们根据使用 MFBIA 计算出的细胞外水(ECW)体积,通过简单的线性回归方法估算出患臂的体积。僵硬组的调整 R2 为 0.044,非僵硬组为 0.729。采用逐步多元线性回归法研究了估算各组患臂体积的重要因素。在非僵硬组中,50 kHz 时的阻抗、体重和身高(调整后的 R2 = 0.724;p = 0.003)是重要的相关因素。在僵硬组,250 kHz 时的阻抗、1 kHz 时的阻抗、体重和身高(调整后的 R2 = 0.705,p = 0.041)之间存在明显关联:考虑到淋巴水肿的特点,同时使用MFBIA和弹性成像可作为估测淋巴水肿的有用生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Biomarkers in lymphedema assessment: integrating elastography and muti-frequency bioimpedance analysis.

Aim: Multi-frequency bioimpedance analysis (MFBIA) is used to measure lymphedema, but it is a biomarker that is sensitive to stiffness. Lymphedema is a condition that can be accompanied by stiffness, but no studies have considered this, so we tried to use non-invasive elastography as a biomarker for stiffness.Methods & results: This retrospective study included 102 patients with lymphedema, divided into two groups according to the elastography strain ratio: stiff group (elastography strain ratio <0.7, n = 48) and non-stiff group (elastography strain ratio >0.7, n = 54). We estimated the volume of the affected arm based the extracellular water (ECW) volume calculated using MFBIA through a simple linear regression method. The adjusted R2 was 0.044 in the stiff group and 0.729 in the non-stiff group. Stepwise multivariate linear regression was used to investigate the significant factors for estimating the affected arm volume for each group. In the non-stiff group, the significantly associated factors were impedance at 50 kHz, weight, and height (adjusted R2 = 0.724; p = 0.003). In the stiff group, significant associations were observed among impedance at 250 kHz, impedance at 1 kHz, weight, and height (adjusted R2 = 0.705, p = 0.041).Conclusion: Considering the characteristics of lymphedema, using MFBIA concurrently with elastography can be useful biomarker for estimating lymphedema.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Biomarkers in medicine
Biomarkers in medicine 医学-医学:研究与实验
CiteScore
3.80
自引率
4.50%
发文量
86
审稿时长
6-12 weeks
期刊介绍: Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
期刊最新文献
N-glycan as new potential biomarker for predicting treatment response in patients with type 2 diabetes mellitus. The predictive value of CK-MB on the curative effect of urokinase combined with LMWH calcium in AMI. Immune nutrition indices are associated with disease activity in rheumatoid arthritis: a cross-sectional study. Baseline triglyceride-glucose, body mass index, end-diastolic internal diameter of the left atria and creatinine are independent predictors for pulmonary hypertension in coronary artery disease patients after percutaneous coronary intervention treatments. Plasma nicotine and its metabolite as biomarkers of tobacco exposure and their relevance to pulmonary nodule.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1